Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

Who can join: the full rules

Key Inclusion Criteria:

1. Confirmed diagnosis of AL amyloidosis as documented historically, as described in the protocol
2. Measurable disease as defined by serum difference between involved and uninvolved free light chains (dFLC), as described in the protocol
3. Adequate hematologic, renal, and hepatic function, as described in the protocol
4. Eastern Cooperative Oncology Group (ECOG) performance score ≤2 at screening

Key Exclusion Criteria:

1. History of other non-AL amyloidosis
2. Greater than or equal to 60% plasmacytosis on a bone marrow biopsy and/or aspirate during screening
3. Presence of lytic bone lesion(s) or plasmacytoma (extramedullary or paraskeletal) on imaging during screening
4. Left ventricular ejection fraction \<40% by echocardiogram during screening, congestive heart failure and acute coronary syndrome or myocardial infarction within 6 months of screening
5. Prior AL amyloidosis treatment

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Study contacts

• Principal investigator: Clinical Trial Management — Regeneron Pharmaceuticals
• Study coordinator: Clinical Trials Administrator
• Email: clinicaltrials@regeneron.com
• Phone: 844-734-6643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Linvoseltamab vs. Daratumumab in high-risk smoldering myeloma

  This study tests whether linvoseltamab can delay progression to active myeloma better than daratumumab in people with high-risk smoldering multiple myeloma.

  Recruiting at 33 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 32 other locations · NCT07393282

• Daratumumab-hyaluronidase added to your myeloma treatment to see if it helps kidney function

  This trial tests whether adding daratumumab-hyaluronidase to the standard bortezomib and dexamethasone therapy improves kidney function in adults newly diagnosed with multiple myeloma and kidney failure.

  Recruiting Phase 2 Eastern Cooperative Oncology Group · Anchorage, Alaska · NCT07085728

• Linvoseltamab versus standard daratumumab‑lenalidomide‑dexamethasone for adults with newly diagnosed, transplant‑ineligible multiple myeloma

  This trial tests whether linvoseltamab works better or is safer than the standard daratumumab‑lenalidomide‑dexamethasone combination in adults newly diagnosed with multiple myeloma who are not eligible for transplant.

  Recruiting at 59 sites Phase 3 European Myeloma Network B.V. · Adelaide and 58 other locations · NCT06932562

• Treatment for newly diagnosed monoclonal immunoglobulin deposition disease

  This study is testing a new combination treatment for people who have just been diagnosed with monoclonal immunoglobulin deposition disease to see if it helps improve their blood health.

  Recruiting at 3 sites Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06418477

• Induction treatment for newly diagnosed multiple myeloma patients with renal failure

  This study is testing a new treatment plan for people with newly diagnosed multiple myeloma and kidney problems to see if it helps them respond better to therapy.

  Recruiting Early Phase 1 Augusta University · Augusta, Georgia · NCT06142396

• Combining CyBorD with Daratumumab for treating kidney disease related to monoclonal gammopathy

  This study is testing a new treatment combining CyBorD and daratumumab to see if it can help people with kidney disease caused by monoclonal gammopathy feel better and improve their kidney function.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 10 other locations · NCT06083922

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.